Biogen Buys Alzheimer’s Compound for $75 Million, Deepening Bet

(Bloomberg) -- Biogen Inc. will buy an experimental Alzheimer’s disease drug from Pfizer Inc. for $75 million, plus additional future payments, extending its wager on therapies for the neurodegener...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.